SUBJECTS : Pharmacotherapy | Real-world Medicine | Disease Management | Drugs | Health Economics | Health Outcome
Drugs in Context: 2023, vol: 12, issue:
- 1)- Andrea De Giglio, Biagio Ricciuti, Giulio Metro. The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks. Drugs in context. 2023, 12:
Cited : 1Read More - 2)- Retno S Wardani, Natalie Schellack, Tamlyn Govender, Abhay N Dhulap, Prapti Utami, Vinod Malve, Yong Chiat Wong. Treatment of the common cold with herbs used in Ayurveda and Jamu: monograph review and the science of ginger, liquorice, turmeric and peppermint. Drugs in context. 2023, 12: Cited : 4Read More
- 3)- Mikhail Kostinov, Oksana Svitich, Alexander Chuchalin, Natalya Abramova, Valery Osiptsov, Ekaterina Khromova, Dmitry Pakhomov, Vitaly Tatevosov, Anna Vlasenko, Vilia Gainitdinova, Kirill Mashilov, Nadezhda Kryukova, Irina Baranova, Anton Kostinov. Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms. Drugs in context. 2023, 12: Cited : 2Read More
- 4)- Yeong Yeh Lee, Vincent Tee. Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report. Drugs in context. 2023, 12: Cited : 1Read More
- 5)- Barbara Moroni, Veronika Óvári, Cristina Nicastro, Raffaella de Salvo, Andreas Ehret. A real-world evidence study evaluating consumer experience of Supradyn Recharge or Supradyn Magnesium and Potassium during demanding periods. Drugs in context. 2023, 12: Cited : 0Read More
- 6)- Yeong Yeh Lee, Vincent Tee. Hepatoprotective effects of silymarin in management of liver injury caused by tuberculosis treatment. Drugs in context. 2023, 12: Cited : 1Read More
- 7)- Ahmed Hashem. Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report. Drugs in context. 2023, 12: Cited : 0Read More
- 8)- Timothy C Hardman, Rob Aitchison, Richard Scaife, Jean Edwards, Gill Slater. The future of clinical trials and drug development: 2050. Drugs in context. 2023, 12: Cited : 6Read More
- 9)- Andrew Merker, Kartik Anne, Justin Rayyan, Milena Murray. Necessity of vancomycin trough concentrations to manage uncomplicated acute bacterial skin and skin structure infections: a laboratory stewardship analysis. Drugs in context. 2023, 12: Cited : 0Read More
- 10)- Virginia Bellido, Cristóbal Morales, Araceli Muñoz Garach, José Manuel García Almeida, Juan Luis Fernández Morera, Beatriz González Aguilera, Martín López de la Torre, Diego Bellido. Descriptive study of a clinical and educational telemedicine intervention in patients with diabetes receiving glargine 300 U/ml (Toujeo) in Spain: results of the T-Coach programme. Drugs in context. 2023, 12: Cited : 1Read More
- 11)- Yeong Yeh Lee, Vincent Tee. Management of non-alcoholic fatty liver disease incidentally detected during other medical assessments. Drugs in context. 2023, 12: Cited : 0Read More
- 12)- Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April An Rose, Francesco Facchinetti. Non-small-cell lung cancer: how to manage -mutated disease. Drugs in context. 2023, 12: Cited : 10Read More
- 13)- Ana Martins, Ana Maria Lé, Tiago Torres. Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far. Drugs in context. 2023, 12: Cited : 3Read More
- 14)- Barbara Tagliaferri, Ludovica Mollica, Raffella Palumbo, Claudia Leli, Alberto Malovini, Matteo Terzaghi, Erica Quaquarini, Cristina Teragni, Stefano Maccarone, Andrea Premoli, Federico Sottotetti. Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR/HER2 breast cancer treated with CDK4/6 inhibitors and endocrine therapy. Drugs in context. 2023, 12: Cited : 0Read More
- 15)- Tanyaporn Chantarojanasiri. Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report. Drugs in context. 2023, 12: Cited : 1Read More
- 16)- Giacomo Caldarola, Arianna Zangrilli, Gerardo Palmisano, Mauro Bavetta, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Luca Bianchi, Clara De Simone, Ketty Peris. Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience. Drugs in context. 2023, 12: Cited : 2Read More
- 17)- Muhammed Ahmed Elhadedy, Ghada El-Kannishy, Ayman F Refaie, Hussein A Sheashaa, Ahmed Halawa. Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet. Drugs in context. 2023, 12: Cited : 2Read More
- 18)- Aldo Torre. Silymarin in the management of liver enzyme activity in steatohepatitis: a case report. Drugs in context. 2023, 12: Cited : 1Read More
- 19)- Giampiero Porzio, Andreia Capela, Raffaele Giusti, Francesca Lo Bianco, Mirella Moro, Giulio Ravoni, Katarzyna Zułtak-Baczkowska. Multidisciplinary approach, continuous care and opioid management in cancer pain: case series and review of the literature. Drugs in context. 2023, 12: Cited : 1Read More
- 20)- Nuria García, Pere Guiró, Jordi Galván, Nigel Crutchley, Morten Praestegaard, Lars Iversen, Tiago Torres. Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD Technology for the treatment of plaque psoriasis on the skin and scalp. Drugs in context. 2023, 12: Cited : 3Read More
- 21)- Rosalba Torrisi, Flavia Jacobs, Chiara Miggiano, Rita De Sanctis, Armando Santoro. HR/HER2 de novo metastatic breast cancer: a true peculiar entity? Drugs in context. 2023, 12: Cited : 4Read More
- 22)- Arturo Cuomo, Anastasios Boutis, Francesca Colonese, Davide Nocerino. High-rate breakthrough cancer pain and tumour characteristics - literature review and case series. Drugs in context. 2023, 12: Cited : 1Read More
- 23)- Diogo Fonseca, Miguel Nogueira, Tiago Torres. Upadacitinib for the treatment of psoriatic arthritis. Drugs in context. 2023, 12: Cited : 3Read More
- 24)- Katayoun Derakhchan, Zhen Lou, Hong Wang, Robert Baughman. Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies. Drugs in context. 2023, 12: Cited : 0Read More
- 25)- Zahra Kassamali Escobar, Todd Bouchard, Cameron Buck, Kamaldeep Sandhu, Chloe Bryson-Cahn. A single-centre experience rolling out an antibiotic stewardship intervention prior to and during the SARS-CoV-2 pandemic 2019-2022. Drugs in context. 2023, 12: Cited : 0Read More
- 26)- Sarah L Anderson, Joel C Marrs. Tirzepatide for type 2 diabetes. Drugs in context. 2023, 12: Cited : 0Read More
- 27)- Arturo Cuomo. Fentanyl in cancer pain management: avoiding hasty judgments and discerning its potential benefits. Drugs in context. 2023, 12: Cited : 0Read More
- 28)- Adil Ramzan, Ghulam Fareed Memon, Asif Ali Shaikh, Mohammad Masood Khoso, Tariq Meher, Adnan Ghafoor, Naveed Ahmed Shehzad, Safian Ahmed, Zunaira Nawaz, Muhammad Rehan, Tariq Saeed, Waqar Taj, Sakhawat Abbass, Ramiz Khan, Hamza Ehsan, Abubakkar Alam, Bilal Manzoor, Muhammad Nawaz Khan, Khalid Mahmood Yahya, Farhan Mukhtiar, Muhammad Asif Javed, Muhammad Usman Sheikh, Danish Janjua, Sumerah Jabeen, Junaid Zafar, Riaz Hussain Khokhar, Madeeha Nazar, Neeta Maheshwary, Muhammad Athar Khan. Efficacy and safety of itopride SR for upper gastrointestinal symptoms in patients with diabetic gastroparesis: real-world evidence from Pakistan. Drugs in context. 2023, 12: Cited : 0Read More
- 29)- Abdulmajeed M Albadi, Mana M Alshahrani, Riyad O Allehebi. Sleep-related breathing disorder (central sleep apnoea) improved coincidentally by medical therapy with fumarates (dimethyl fumarate). Drugs in context. 2023, 12: Cited : 0Read More
- 30)- Kayla R Stover, Brandon K Hawkins, J Myles Keck, Katie E Barber, David A Cretella. Antifungal resistance, combinations and pipeline: oh my! Drugs in context. 2023, 12: Cited : 6Read More
- 31)- Marilyne Jarjour, Anique Ducharme. Optimization of GDMT for patients with heart failure and reduced ejection fraction: can physiological and biological barriers explain the gaps in adherence to heart failure guidelines? Drugs in context. 2023, 12: Cited : 0Read More
- 32)- . Corrigendum: real-world management of abnormal scarring using topical silicone gel: expert consensus and case series from the Asian SCARS Expert Group. Drugs in context. 2023, 12: Cited : 0Read More
- 33)- Alexander Kc Leung, Benjamin Barankin, Joseph M Lam, Kin Fon Leong. Childhood guttate psoriasis: an updated review. Drugs in context. 2023, 12: Cited : 2Read More
- 34)- Vassilia Theodorou, Catherine Beaufrand, Hélène Eutamene. Effect of xyloglucan associations with gelatin or gelose on Escherichia coli-derived lipopolysaccharide-induced enteritis in rats. Drugs in context. 2023, 12: Cited : 0Read More
- 35)- Rebecca J Stinson, Alyn H Morice, Basir Ahmad, Laura R Sadofsky. Ingredients of Vicks VapoRub inhibit rhinovirus-induced ATP release. Drugs in context. 2023, 12: Cited : 0Read More
- 36)- Sofia Faria, Egídio Freitas, Tiago Torres. Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date. Drugs in context. 2023, 12: Cited : 1Read More
- 37)- Enrique Casado, Ester Costa, Pedro Mezquita-Raya, Rubén Andújar-Espinosa, José Luis Neyro. Calcifediol in the management of vitamin D deficiency-related skeletal and extraskeletal diseases: overview and clinical cases. Drugs in context. 2023, 12: Cited : 1Read More
- 38)- Alejandro Bimbo Diaz, Jeremy Chow, Fan Kee Hoo, Kok Wei Koh, Gary Chin Keong Lee, Wee Siong Teo, Narayanaswamy Venketasubramanian, Chun-Chieh Wang, Radhika Mehta. Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region. Drugs in context. 2023, 12: Cited : 0Read More
- 39)- . Corrigendum: Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring - a focus on the Italian system. Drugs in context. 2023, 12: Cited : 0Read More
- 40)- Guido Mannaioni, Fabio Lugoboni. Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring - a focus on the Italian system. Drugs in context. 2023, 12: Cited : 1Read More
- 41)- Mikhail P Kostinov, Vilia V Gainitdinova, Svetlana V Kazharova, Anna E Vlasenko, Vflentina B Polishchuk, Kirill V Mashilov. Use of immunomodulatory therapy as part of comprehensive treatment of non-severe community-acquired pneumonia and its long-term results. Drugs in context. 2023, 12: Cited : 1Read More
- 42)- Jonathan Wadsley, Alan Christie, Roopinder Gillmore, Amy Trinh, Rachel Greig. Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases. Drugs in context. 2023, 12: Cited : 0Read More
- 43)- Milena M Murray, Lara Fakhouri, Spencer E Harpe. META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports. Drugs in context. 2023, 12: Cited : 1Read More
- 44)- Paulo Henrique Feitosa. Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential. Drugs in context. 2023, 12: Cited : 3Read More
- 45)- Yuko Hasebe, Yusuke Karasawa, Kazutaka Nozawa. Dietary therapy for patients with chronic pancreatitis in Japan: a cross-sectional online survey of physicians and registered dietitians. Drugs in context. 2023, 12: Cited : 0Read More
- 46)- Andrew Smith, Peter Kardos, Oliver Pfaar, Winfried Randerath, Guillermo Estrada Riolobos, Fulvio Braido, Laura Sadofsky. The treatment of mild upper respiratory tract infections - a position paper with recommendations for best practice. Drugs in context. 2023, 12: Cited : 1Read More
- 47)- Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, Helen Yearley, Wolfgang Junker, Nina Gruber, Sibyll Escher, Katrin Biereth, Sima Melnik, Julia Puschmann. Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data. Drugs in context. 2023, 12: Cited : 4Read More
- 48)- Alexander Kc Leung, Benjamin Barankin, Joseph M Lam, Kin Fon Leong, Kam Lun Hon. Tinea pedis: an updated review. Drugs in context. 2023, 12: Cited : 4Read More
- 49)- Xiaonan Yang, Visnu Lohsiriwat, Frank Chun Shin Chang, Tan Thiam Chye, Catherine J Howard, Liang Qiao, Steven W Shaw, Tu Nguyen Anh Tran, Chan Yung, Daniel Dellosa, Dinesh Nagrale. Real-world management of abnormal scarring using topical silicone gel: expert consensus and case series from the Asian SCARS Expert Group. Drugs in context. 2023, 12: Cited : 1Read More
- 50)- Darren Mc Poon, Kuen Chan, Angus Kwong-Chuen Leung, Brian Ng, Foon-Yiu Cheung, Steven Wai-Kwan Siu, . Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors. Drugs in context. 2023, 12: Cited : 2Read More
